Contraindicated (one)bortezomib will raise the degree or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or reasonable CYP2C19 inhibitors may well maximize mavacamten systemic publicity, resulting in coronary heart failure because of systolic dysfunction. Other effects, such as a pores and skin rash, will not be major https://tussilagone33219.blogrenanda.com/32616453/everything-about-cp-866087